Phase 2, Randomized, Double-Blind, Multiple-Dose Level, Placebo Controlled, Single Intravenous Dose, Parallel Efficacy and Safety Study of NRX-1074 in Subjects With Major Depressive Disorder

Trial Profile

Phase 2, Randomized, Double-Blind, Multiple-Dose Level, Placebo Controlled, Single Intravenous Dose, Parallel Efficacy and Safety Study of NRX-1074 in Subjects With Major Depressive Disorder

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Mar 2016

At a glance

  • Drugs Apimostinel (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Sponsors Naurex
  • Most Recent Events

    • 22 Jun 2015 According to a Naurex Inc. media release, the results of this trial will be presented at the 55th Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP).
    • 22 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 12 May 2015 According to Naurex media release, the data from this trial will be presented at 70th Annual Scientific Meeting of the Society of Biological Psychiatry (SOBP), held at the Fairmont Royal York Hotel in Toronto.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top